The ACOEM Mold Paper: $500/Hour Expert Witnesses and What the Science Actually Shows

If a doctor has told you "the science doesn't support mold causing illness," that claim traces back to a single 2002 position statement from the American College of Occupational and Environmental Medicine (ACOEM). Three defense expert witnesses wrote it. ACOEM's own reviewers called it "a defense argument" before it went to print. It was published two months later, essentially unchanged. And in 2015, ACOEM pulled it from circulation, and per VICE's reporting the organization treated it as no longer scientifically relevant or accurate.

The science was never on the paper's side. A literature review covering 114 epidemiological studies from 2011 to 2018 found that 112 of them (98.2%) reported adverse health effects — single- or multi-system — from indoor mold and dampness exposure. The consensus didn't need to catch up to the ACOEM paper. The ACOEM paper was manufactured against it.

If that story sounds familiar, and you're wondering what steps actually make sense for your situation, start with objective lab testing that measures biomarkers linked to mold-related inflammation. You'll be working from data, not from conclusions shaped by a discredited paper.

Follow the money

The 2002 ACOEM paper concluded that "current scientific evidence does not support the proposition that human health has been adversely affected by inhaled mycotoxins in home, school, or office environment" (Hardin, Kelman, and Saxon, JOEM 2003). For over a decade, that sentence became the most cited line in mold litigation, insurance denials, and clinical dismissals.

The authors weren't disinterested scientists.

Bryan Hardin and Bruce Kelman ran GlobalTox (later renamed Veritox), a consulting firm that provided defense expert witness services in mold cases. Court records show they billed $375 to $500 per hour for this work. Andrew Saxon, an allergist-immunologist at UCLA, billed $510 per hour for depositions and $720 per hour for courtroom testimony. The Wall Street Journal reported that Saxon earned between $250,000 and $500,000 annually from defense expert work. None of these financial relationships were disclosed when the paper was published (Wall Street Journal, 2007).

This wasn't a secret inside ACOEM. Internal emails obtained by the Wall Street Journal show that Jonathan Borak, who chaired the scientific advisory panel, told Hardin directly that the paper "would be prepared by you and your GlobalTox colleagues." After the draft circulated, ACOEM's own reviewers wrote that they "find the current version, much revised, to still be a defense argument." At least one reviewer, Jay Portnoy, objected to what he perceived as an agenda driving the paper.

Two months later, ACOEM published it essentially unchanged.

The methodology tells you everything

A neutral scientist investigating whether chronic mold exposure causes illness wouldn't design an analysis around single-dose rodent toxicology studies. But that's exactly what this paper did.

To evaluate whether chronic human inhalation of indoor mold causes illness, the authors relied on six rodent studies. All but one used single-dose tracheal instillation, where a researcher injects a bolus of toxin directly into an animal's airway in a single event. Extrapolating from acute, single-dose animal data to chronic human inhalation exposure violates basic principles of both toxicology and epidemiology (Craner 2008).

The paper also built a mathematical model for mycotoxin accumulation in human tissue. That model assumed mycotoxin half-lives of "days," when later research showed that some of those half-lives were substantially understated. The model ignored immune system stimulation from mold spore fragments entirely. The U.S. Government Accountability Office independently confirmed methodological problems in the analyses, noting the Institute of Medicine's 2004 finding that biological plausibility existed for Stachybotrys health effects.

That specific methodological choice (which produces the result most useful for defense litigation) is what makes the paper's conflicts of interest visible in the science itself.

And it's worth remembering: this was a position statement, not peer-reviewed primary research. It generated no new data. It wasn't subjected to the scrutiny that original clinical research receives. Yet it was cited for over a decade as though it represented the scientific consensus.

How one paper shaped a decade of denials

The paper didn't stay on a shelf. Within 14 days of publication, an insurance industry newsletter endorsed its conclusions. The Manhattan Institute, a think tank with documented ties to corporate defense interests, paid GlobalTox $40,000 for a lay version. That version was distributed through the U.S. Chamber of Commerce to reach the broadest possible audience (Armstrong, WSJ 2007).

The courtroom impact was immediate. Dr. Ritchie Shoemaker, who has treated over 14,000 patients with mold-related illness, later observed: "After 2003, there were no cases that I participated in where defense did not quote ACOEM."

Attorneys who represented mold-exposed families documented the effect on their clients. Elizabeth Eilander, an attorney who worked on the Fraser family case in New York, characterized the paper as defense experts authoring work under an official guise. Attorney Brian Witzer, representing a client in Manhattan Beach, California, described a chilling effect: plaintiffs unable to find representation or to afford appealing a dismissal or a ruling excluding their experts.

The paper also spawned derivative publications. The AAAAI issued its own 2006 position statement with Saxon as a co-author, built on the ACOEM paper's unverified mathematical model. Academics published derivative papers (including "Mold Hysteria" by Chang and Gershwin) that accepted the original model as fact without independent verification. None of these contained human data. All were cited in defense litigation.

If you've been told by a doctor that "the science doesn't support" mold illness, or if an insurer denied your claim citing scientific consensus, there's a good chance the chain of authority traces back to this one paper.

What 112 out of 114 studies actually found

Here's the part the ACOEM paper tried to preempt.

Dooley and McMahon (2020) reviewed 114 epidemiological studies published between 2011 and 2018. Of those, 112 (98.2%) were supportive of single- or multi-system adverse health effects from indoor mold and dampness exposure. Seventy-nine of those studies showed strong associations, with odds ratios or relative risks of 2.0 or greater. This review was co-authored by Dr. Scott McMahon, MoldCo's Medical Director, who has treated over 2,000 patients with mold-related illness.

The World Health Organization's 2009 guidelines on indoor air quality recognized the health effects of dampness and mold, noting that air sampling captures less than 0.2% of relevant biological fragments. The WHO's conclusions directly contradict the ACOEM paper's central claim.

Holzheimer and Hakim (2025) documented 4.6 million U.S. asthma cases attributable to dampness and mold, with an annual cost of $3.5 billion.

Peer dissent emerged within the allergy and immunology community itself. Independent reviewers characterized the position paper's analysis as methodologically unsound, particularly its extrapolation from single-dose rodent studies to chronic human inhalation exposure (Craner 2008). The objections weren't coming from the margins. They were coming from within the same specialty.

ACOEM's own quiet admission

ACOEM removed the paper from its website in early 2015 without a public announcement. Per VICE's reporting, the organization sunsetted the paper with no announcement, treating it as no longer scientifically relevant or accurate. The AAAAI had already sunsetted its related 2006 paper in 2011. The Journal of Allergy and Clinical Immunology ran a correction disclosing the conflicts of interest of Saxon and other authors.

VICE reported in 2015 that mold-related insurance claims had reached $2.5 billion before the paper was widely deployed.

The organizations that published these papers no longer stand behind them. But the paper is still cited in litigation, still referenced in clinical training, and still shaping what some doctors tell patients about mold exposure symptoms.

What we're not claiming

This article focuses on the ACOEM 2002 position statement, its authorship, and the documented conflicts of interest surrounding its creation. It doesn't review all literature on mold-related illness or present a complete clinical framework for diagnosis and treatment.

The Dooley and McMahon (2020) review covers epidemiological studies from 2011 to 2018. It's the most complete post-ACOEM literature review available, but it doesn't capture every study in the field.

The dollar amounts cited for author billing rates and the Manhattan Institute payment come from court records reported by the Wall Street Journal and confirmed under oath.

Dr. Scott McMahon, MoldCo's Medical Director, co-authored the Dooley-McMahon 2020 review cited throughout this article. We disclose that because transparency is exactly the standard the ACOEM paper failed to meet.

Frequently asked questions

Was the ACOEM mold paper retracted?

Not formally retracted in the traditional academic sense. ACOEM "sunsetted" the paper in early 2015, removing it from their website; per VICE's reporting the organization treated it as no longer scientifically relevant or accurate. The practical effect is the same: the organization that published it no longer endorses it. But because it wasn't a formal retraction, the paper still appears in some databases and is still cited in legal proceedings.

Who funded the ACOEM mold position statement?

The authors' defense expert witness practices funded their livelihoods. Hardin and Kelman ran GlobalTox (later Veritox), billing $375 to $500 per hour for defense work in mold cases. Saxon earned $250,000 to $500,000 annually from similar work. The Manhattan Institute paid $40,000 for a lay version distributed through the U.S. Chamber of Commerce. These relationships weren't disclosed when the paper was published.

Does the science support mold causing illness?

Yes. 112 of 114 epidemiological studies published between 2011 and 2018 reported adverse health effects — single- or multi-system — from indoor mold and dampness. The World Health Organization and the U.S. GAO recognize that indoor mold exposure can cause illness beyond simple allergy. The body of evidence is large and still growing.

My doctor cited this paper to dismiss my symptoms. What should I do?

Your doctor may not know the paper was written by paid defense witnesses, flagged by ACOEM's own reviewers as advocacy, and removed from circulation in 2015. Most physicians rely on summaries and guidelines rather than investigating the provenance of individual papers. You can share the citations in this article. You can also take a concrete first step: if you suspect your environment may be contributing to how you feel, getting objective lab data on biomarkers associated with mold-related inflammation gives you and your doctor something specific to discuss.

Is the ACOEM paper still used in court?

Yes. Despite being sunsetted in 2015, the paper and its derivative publications continue to appear in mold litigation. Dr. Shoemaker noted that "after 2003, there were no cases that I participated in where defense did not quote ACOEM." Attorneys have documented a chilling effect on plaintiffs' ability to find representation.

If you've been dismissed by a doctor who cited this paper, or if you're still wondering whether your environment could be contributing to your symptoms, a clear path forward starts with the right tests. MoldCo can help you rule it in or rule it out.

Any health-related claims made on this site have not been evaluated by the Food and Drug Administration (FDA). The information provided on this site is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. MoldCo assumes no responsibility or liability for any errors or omissions in the content of the references, nor for any actions taken in reliance thereon.